AU2015312430B2 - Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof - Google Patents

Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof Download PDF

Info

Publication number
AU2015312430B2
AU2015312430B2 AU2015312430A AU2015312430A AU2015312430B2 AU 2015312430 B2 AU2015312430 B2 AU 2015312430B2 AU 2015312430 A AU2015312430 A AU 2015312430A AU 2015312430 A AU2015312430 A AU 2015312430A AU 2015312430 B2 AU2015312430 B2 AU 2015312430B2
Authority
AU
Australia
Prior art keywords
levodopa
carbidopa
dopamine
inhibitor
entacapone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2015312430A
Other languages
English (en)
Other versions
AU2015312430A1 (en
Inventor
Roger Bolsoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lobsor Pharmaceuticals AB
Original Assignee
Lobsor Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE1451034A external-priority patent/SE538425C2/en
Application filed by Lobsor Pharmaceuticals AB filed Critical Lobsor Pharmaceuticals AB
Publication of AU2015312430A1 publication Critical patent/AU2015312430A1/en
Application granted granted Critical
Publication of AU2015312430B2 publication Critical patent/AU2015312430B2/en
Priority to AU2020239682A priority Critical patent/AU2020239682B2/en
Priority to AU2022200291A priority patent/AU2022200291B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015312430A 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof Active 2038-09-01 AU2015312430B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020239682A AU2020239682B2 (en) 2014-09-04 2020-09-23 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
AU2022200291A AU2022200291B2 (en) 2014-09-04 2022-01-18 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1451034A SE538425C2 (en) 2014-09-04 2014-09-04 Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
SE1451034-1 2014-09-04
SE1550344 2015-03-24
SE1550344-4 2015-03-24
PCT/SE2015/050939 WO2016036308A1 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020239682A Division AU2020239682B2 (en) 2014-09-04 2020-09-23 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof

Publications (2)

Publication Number Publication Date
AU2015312430A1 AU2015312430A1 (en) 2017-03-30
AU2015312430B2 true AU2015312430B2 (en) 2020-06-25

Family

ID=55440194

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015312430A Active 2038-09-01 AU2015312430B2 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
AU2020239682A Active 2038-09-01 AU2020239682B2 (en) 2014-09-04 2020-09-23 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
AU2022200291A Active 2038-09-01 AU2022200291B2 (en) 2014-09-04 2022-01-18 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020239682A Active 2038-09-01 AU2020239682B2 (en) 2014-09-04 2020-09-23 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
AU2022200291A Active 2038-09-01 AU2022200291B2 (en) 2014-09-04 2022-01-18 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof

Country Status (16)

Country Link
US (5) US10071069B2 (enExample)
EP (3) EP3782617B1 (enExample)
JP (2) JP6622310B2 (enExample)
CN (1) CN107072973A (enExample)
AU (3) AU2015312430B2 (enExample)
CA (2) CA3175785A1 (enExample)
DK (2) DK3782617T3 (enExample)
ES (2) ES2973289T3 (enExample)
FI (1) FI3782617T3 (enExample)
HR (2) HRP20240314T1 (enExample)
HU (2) HUE052857T2 (enExample)
PL (2) PL3782617T3 (enExample)
PT (2) PT3188725T (enExample)
RS (1) RS65337B1 (enExample)
SI (2) SI3188725T1 (enExample)
WO (1) WO2016036308A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973289T3 (es) 2014-09-04 2024-06-19 Lobsor Pharmaceuticals Ab Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
RU2017120184A (ru) * 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
SG11201808713YA (en) * 2016-04-11 2018-11-29 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
US20180021280A1 (en) * 2016-07-20 2018-01-25 Abbvie Inc. Levodopa and Carbidopa Intestinal Gel and Methods of Use
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
WO2018146194A1 (en) 2017-02-13 2018-08-16 Bayer Animal Health Gmbh Liquid composition containing pradofloxacin
CN111902136A (zh) * 2017-12-28 2020-11-06 瑞璞鑫(苏州)生物科技有限公司 用于预防和/或治疗肥胖症和相关代谢性疾病的托卡朋
CN118121710A (zh) * 2018-03-23 2024-06-04 劳波索尔制药有限公司 用于治疗神经退行性疾病的药物组合物的连续施用
EP3593819A1 (en) 2018-07-10 2020-01-15 Medday Pharmaceuticals Compositions for therapeutic uses containing 5-htp and carbidopa
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
TWI831896B (zh) * 2018-12-18 2024-02-11 美商美國禮來大藥廠 用於治療多巴胺性cns病症之ly3154207劑量療法
JP7506371B2 (ja) * 2020-01-20 2024-06-26 国立大学法人浜松医科大学 ドーパミン減少抑制剤
JP2023517690A (ja) * 2020-03-13 2023-04-26 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 微粉化オピカポン
CN111643493B (zh) * 2020-05-26 2023-01-10 上海京新生物医药有限公司 一种高浓度左旋多巴制剂及其制备方法及其应用
WO2022158991A1 (en) * 2021-01-20 2022-07-28 Bial-Portela & Ca., S.A. Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa
WO2025162373A1 (en) * 2024-01-30 2025-08-07 National Institute Of Biological Sciences, Beijing Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098661A1 (en) * 2008-02-06 2009-08-13 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
US20130253056A1 (en) * 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004348D0 (en) 1990-02-27 1990-04-25 Orion Yhtymae Oy New use of catechol derivatives and their physiologically acceptable salts and esters
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
HK1041441A1 (zh) * 1998-11-10 2002-07-12 Teva Pharmaceutical Industries, Ltd. 包含l-多巴乙酯的可分散组合物
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
MXPA06002344A (es) 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20060222703A1 (en) 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
RU2484815C2 (ru) 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
US8741342B2 (en) 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
ES2627655T3 (es) * 2009-05-19 2017-07-31 Neuroderm Ltd Composiciones para la administración continua de inhibidores de DOPA descarboxilasa
JP5902705B2 (ja) 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
JP6472391B2 (ja) 2013-03-13 2019-02-20 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ パーキンソン病の治療方法
ES2973289T3 (es) 2014-09-04 2024-06-19 Lobsor Pharmaceuticals Ab Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
SE538425C2 (en) 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098661A1 (en) * 2008-02-06 2009-08-13 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
US20130253056A1 (en) * 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NYHOLM, D. et al., "Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial", Eur. J. Neurol., (2012-06), vol. 19, no. 6, pages 820 - 826 *
SOLLA PAOLO et al., "Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo", Neuropsychiatric disease and treatment, (20100000), vol. 6, pages 4 83 - 490 *

Also Published As

Publication number Publication date
US10786472B2 (en) 2020-09-29
EP3782617B1 (en) 2024-01-03
CA2959307A1 (en) 2016-03-10
SI3188725T1 (sl) 2021-04-30
DK3782617T3 (da) 2024-03-04
HRP20240314T1 (hr) 2024-05-24
US11413262B2 (en) 2022-08-16
SI3782617T1 (sl) 2024-04-30
US20250041257A1 (en) 2025-02-06
JP2020045353A (ja) 2020-03-26
DK3188725T3 (da) 2021-01-18
US20180338944A1 (en) 2018-11-29
RS65337B1 (sr) 2024-04-30
AU2022200291B2 (en) 2024-01-25
AU2020239682B2 (en) 2021-12-23
JP6622310B2 (ja) 2019-12-18
EP3782617A1 (en) 2021-02-24
CA2959307C (en) 2023-03-28
HUE052857T2 (hu) 2021-05-28
PT3188725T (pt) 2021-01-27
PL3782617T3 (pl) 2024-06-24
PT3782617T (pt) 2024-02-29
PL3188725T3 (pl) 2021-08-02
EP3188725A4 (en) 2018-04-25
US20170231937A1 (en) 2017-08-17
ES2844500T3 (es) 2021-07-22
WO2016036308A1 (en) 2016-03-10
US10071069B2 (en) 2018-09-11
EP3188725B1 (en) 2020-10-28
AU2022200291A1 (en) 2022-02-10
US20210023033A1 (en) 2021-01-28
CA3175785A1 (en) 2016-03-10
JP6889231B2 (ja) 2021-06-18
FI3782617T3 (fi) 2024-03-13
AU2020239682A1 (en) 2020-10-15
US12156858B2 (en) 2024-12-03
AU2015312430A1 (en) 2017-03-30
EP4356907A1 (en) 2024-04-24
ES2973289T3 (es) 2024-06-19
CN107072973A (zh) 2017-08-18
HUE066097T2 (hu) 2024-07-28
US20220362193A1 (en) 2022-11-17
HRP20210025T1 (hr) 2021-03-05
JP2017527623A (ja) 2017-09-21
EP3188725A1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
US12156858B2 (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
US10555922B2 (en) Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
US20250213518A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
HK40110793A (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
HK40044749A (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone
HK40044749B (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: LECIGON LEVODOPA

Filing date: 20230901

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: LECIGON LEVODOPA

Filing date: 20230901

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: LECIGON LEVODOPA

Filing date: 20230901

Extension date: 20380901